Drugs for Obesity; Weight-loss drug Qnexa gets thumbs-down from FDA panel



FDA Weighs Fate of Qnexa for Weight Loss, Again

Drug previously rejected because of possible heart problems, birth defects.

By Denise Mann, HealthDay News

Don't Miss This

Sign Up for OurDiet and NutritionNewsletter

Thanks for signing up!You might also like these other newsletters:

TUESDAY, Feb. 21, 2012 (HealthDay News) —The U.S. Food and Drug Administration plans to take a second look at the weight loss pill Qnexa on Wednesday, after initially rejecting it because of concerns about heart problems and possible birth defects.

While effective at reducing weight, the drug, manufactured by Vivus Inc., was denied approval in 2010 because of its potential side effects. An FDA advisory panel will now review two years of data; when advisers last voted on Qnexa, only one year's worth of follow-up data was available.

The drug combines the appetite suppressant phentermine and the anti-seizure/migraine drug topiramate. Phentermine was once widely prescribed as the "phen" part of the fen-phen weight loss drug. This combo was withdrawn from the market after its use was linked to high blood pressure in the lungs and heart valve disease. The problems were related to the "fen" or fenfluramine part of the combination, not the phentermine.

No new weight-loss drug has been approved in the United States in the past 13 years, according to published reports. As it stands, Xenical is the only FDA-approved drug specifically for long-term use — up to a year — for weight loss. Xenical is sold over-the-counter as Alli. However, other drugs may be used off label to promote weight loss.

Last April, a study funded by Vivus found that obese patients taking Qnexa lost an average 22 pounds over a year, while also lowering their blood pressure and cholesterol levels.

Dr. Louis Aronne, founder and director of the Comprehensive Weight Control Program at New York-Presbyterian Hospital/Weill Cornell Medical Center in New York City, is cautiously optimistic that Vivus did a good job responding to FDA safety concerns, and that the FDA will give the drug its nod of approval, with some caveats. Aronne was not involved in the trials but has been an adviser to Vivus and other companies developing weight loss medications.

"I am not as pessimistic as most people," he said.

Vivus has reported that Qnexa may increase the risk of cleft lip in babies of women who use the drug while pregnant. Aronne said the birth defect concern could be addressed through education on who should and should not use the new drug.

"We have learned our lessons with weight loss drugs," he said. "They need to be used in the right people under the right circumstances." The heart risks need to be weighed against reductions in heart disease risk factors that come with weight loss, he said.

Qnexa is not any riskier than bariatric surgery, according to Aronne. "The problem is that it can be distributed more widely," he said. He hopes for a compromise that allows the new compound to be prescribed, but not misused. "Once new medications are approved, local medical boards will need to enforce rules and make sure these medications are prescribed appropriately to the right candidates," he said. "We don't want to open up pill mills."

One thing is clear, he said: More options to treat obesity are needed. "For hypertension, there are 120 medications in nine categories," Aronne said. "We need new options and we need to get physicians thinking about obesity and obesity treatments."

Dr. Scott Kahan, an obesity expert at Johns Hopkins University in Baltimore and director of the National Center for Weight and Wellness in Washington, D.C., agreed. He is optimistic about the FDA's upcoming decision on Qnexa.






Video: Losing Weight With Qsymia and Belviq

FDA Weighs Fate of Qnexa for Weight Loss, Again
FDA Weighs Fate of Qnexa for Weight Loss, Again images

2019 year
2019 year - FDA Weighs Fate of Qnexa for Weight Loss, Again pictures

FDA Weighs Fate of Qnexa for Weight Loss, Again advise
FDA Weighs Fate of Qnexa for Weight Loss, Again recommendations photo

FDA Weighs Fate of Qnexa for Weight Loss, Again images
FDA Weighs Fate of Qnexa for Weight Loss, Again images

FDA Weighs Fate of Qnexa for Weight Loss, Again FDA Weighs Fate of Qnexa for Weight Loss, Again new pics
FDA Weighs Fate of Qnexa for Weight Loss, Again new foto

images Dr. Mallikas 5 Fast Facts: How Soda Affects Kids Health
picture Greatist Workout of the Day: Friday, May 2nd

Lower Your Stroke Risk By 10
Net-a-Porter founder to launch designer sale siteFashion Then and Now According To Melody NazarianTaryn Manning Has a Strange BeautySecret

Singapore Airlines Business Class: How To Get More From Your Flight
The Gross Truth About Washing Your PJs

2014s Key Men’s Hairstyle Trend
27 of the Coolest Boots Youll Live in This Autumn6 Clean Foods That Will Boost Your Mood and Beat Stress This Season

Watch FDA Weighs Fate of Qnexa for Weight Loss, Again video
Watch FDA Weighs Fate of Qnexa for Weight Loss, Again video

Forum on this topic: FDA Weighs Fate of Qnexa for Weight , fda-weighs-fate-of-qnexa-for-weight/
Forum on this topic: FDA Weighs Fate of Qnexa for Weight , fda-weighs-fate-of-qnexa-for-weight/ , fda-weighs-fate-of-qnexa-for-weight/

Related News


I Have Cancer and Im Mad As Hell
Yellow Dal With Quinoa
Catch A Fire: August 2009
How to Treat Shock
How to Protect Cloth Car Seats
Dude, What Happened to Daniel Craig’s Face
Creamy Chocolate-Filled Puffs
Philips DirectLife Advanced Activity Monitor
Jane Fallon – 2011 Mentor
Healthy Recipes for a Post-Holiday Reset
How to Make Vanilla Extract



Date: 19.01.2019, 05:21 / Views: 54433